Vaccination

CSL Limited said during its annual meeting that with US influenza vaccination rates down 12%-14%, it will delay the separation of its vaccine business Seqirus beyond the end of financial year 2026.

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.